Edesa Biotech, Inc. (EDSA) — Financial statements
Income statement, balance sheet, and cash flow for Edesa Biotech, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.12↓35.9% | 0.19↑1.4% | 0.18↑55.2% | 0.12↓0.5% | 0.12 | |
| Gross Profit | -0.12↑35.9% | -0.19↓1.4% | -0.18↓55.2% | -0.12↑0.5% | -0.12 | |
| Operating Expenses | ||||||
| R&D Expenses | 4↑27.3% | 3↓39.9% | 5↓64.0% | 13↓25.7% | 18 | |
| General & Administrative Expenses | 4↑2.7% | 4↓6.7% | 4↓12.1% | 5↓12.2% | 6 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 4↑2.7% | 4↓6.7% | 4↓12.1% | 5↓12.2% | 6 | |
| Other Expenses | -0.12 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 8↑11.1% | 7↓23.9% | 9↓49.8% | 18↓22.4% | 24 | |
| Total Costs & Expenses | 8↑12.8% | 7↓23.9% | 9↓49.8% | 18↓22.4% | 24 | |
| Operating Results | ||||||
| Operating Income | -8↓12.8% | -7↑23.9% | -9↑49.8% | -18↑22.4% | -24 | |
| Depreciation & Amortization | 0.12↓35.9% | 0.19↑1.4% | 0.18↑55.2% | 0.12↓0.5% | 0.12 | |
| EBITDA | -7↓18.1% | -6↑26.9% | -8↑53.0% | -17↓31.8% | -13 | |
| EBIT | -7↓16.5% | -6↑26.3% | -8↑52.3% | -18↓31.5% | -13 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↓98.3% | 0.15↓47.0% | 0.29↑456206.7% | 0.00↓99.4% | 0.01 | |
| Interest Income | 0.00↓98.3% | 0.15↓47.0% | 0.29↑456206.7% | 0.00↓99.4% | 0.01 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -0.73↑14.0% | -0.85↑0.4% | -0.85↓3.2% | -0.82↑92.0% | -10 | |
| Other Income / Expenses | 0.73↓14.0% | 0.85↓0.4% | 0.85↑3.2% | 0.82↓92.0% | 10 | |
| Income Before Tax | -7↓16.5% | -6↑26.3% | -8↑52.3% | -18↓31.5% | -13 | |
| Income Tax Expense | 0.00↑0.0% | 0.00↑0.0% | 0.00↑0.0% | 0.00↑0.0% | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -7↓16.5% | -6↑26.3% | -8↑52.3% | -18↓31.5% | -13 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -7↓16.5% | -6↑26.3% | -8↑52.3% | -18↓31.5% | -13 | |
| Bottom-Line Net Income | -7↓16.5% | -6↑26.3% | -8↑52.3% | -18↓31.5% | -13 | |
| EPS (Basic) | -1.27↑34.2% | -1.93↑34.1% | -2.93↑65.0% | -8.37↓8.1% | -7.74 | |
| EPS (Diluted) | -1.27↑34.2% | -1.93↑34.1% | -2.93↑65.0% | -8.37↓8.3% | -7.73 | |
| Weighted Average Shares | 6↑77.5% | 3↑11.9% | 3↑36.4% | 2↑21.5% | 2 | |
| Weighted Average Diluted Shares | 6↑77.5% | 3↑11.8% | 3↑36.4% | 2↑21.5% | 2 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.